Skip to main
HOWL

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics demonstrates a solid financial foundation through its innovative use of the proprietary PREDATOR platform, which positions the company to advance its unique INDUKINE therapies targeting the tumor microenvironment. The adjustment to Core FFO guidance, reflecting a midpoint increase of $0.03, indicates the company's ability to navigate costs effectively while still achieving growth. Additionally, the impressive metrics of 4.3% blended rent growth and 4.1% same-store NOI expansion showcase a thriving operational landscape, enhancing investor confidence in the company's future prospects.

Bears say

Werewolf Therapeutics Inc. faces a negative outlook due to lowered growth expectations reflected in its financial metrics. The company's performance indicators suggest a decline in revenue, alongside a 3.8% year-over-year rise in expenses, resulting in a 2.6% decline in net operating income (NOI). Additionally, average effective rental rates have decreased by 50 basis points year-over-year, attributed to a significant decline in new lease rates, indicating challenges in achieving desired growth against the backdrop of market supply conditions.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.